LTBR agonists in anti-cancer combination therapy

The present invention relates to a combination comprising a Treg scavenger and an LTBR agonist. Such combinations are particularly useful in the treatment of cancer. Examples are the production of mouse antagonist CCR8VHH and CCR8VHH-Fc fusions, as well as LTBR agonistic single domain antibodies. An anti-CCR8 antibody VHH-Fc and an LTBR agonist VHH have been tested in an MC38 homologous mouse model and show that 100% of the test mouse survives after 25 days, while the survival rate of the VHH that binds to LTBR is 60% and the survival rate of the VHH-Fc that binds to CCR8 is 70%. The effect of a combination of an anti-CTLA4 antibody and an LTBR agonist (VHH-16) on tumor growth in an MC38 homologous mouse model is also illustrated, leading to the creation of a synergistic effect and reduction of tumor load. 本发明涉及包含Treg清除剂和LTBR激动剂的组合。这样的组合特别可用于治疗癌症。示例是小鼠拮抗剂CCR8VHH和CCR8VHH-Fc融合体以及LTBR激动性单域抗体的产生。一种抗CCR8抗体VHH-Fc和一种LTBR激动剂VHH已在MC38同系小鼠模型中进行了测试，并且显示25天后100％的测试小鼠存活，而结合LTBR的VHH的存活率为60％，且结合CCR8的VHH-Fc的存活率为70％。还举例说明了抗CT